Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ca channel blocker and heart failure].

Shintaro Kinugawa1, Hiroyuki Tsutsui

  • 1Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine.

Clinical Calcium
|October 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.

European heart journal·2021
Same author

Efficacy of thromboelastography in the management of anticoagulation for veno-venous extracorporeal membrane oxygenation in a coronavirus disease 2019 patient: A case report.

Medicine·2021
Same author

JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias.

Circulation journal : official journal of the Japanese Circulation Society·2021
Same author

Beta-Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy.

Journal of the American Heart Association·2021
Same author

Nanoparticle-Mediated Simultaneous Targeting of Mitochondrial Injury and Inflammation Attenuates Myocardial Ischemia-Reperfusion Injury.

Journal of the American Heart Association·2021
Same author

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese <i>ob/ob</i> Mice.

Frontiers in cardiovascular medicine·2021

Calcium channel blockers (CCBs) initially showed promise for heart failure (HF) but short-acting versions increased risks. Newer CCBs offer potential therapeutic benefits for chronic HF patients.

Area of Science:

  • Cardiovascular Pharmacology
  • Pharmacology of Calcium Channel Blockers

Context:

  • Calcium channel blockers (CCBs) target L-type calcium channels in vascular smooth muscle, lowering blood pressure.
  • Initial expectations suggested CCBs could treat heart failure (HF) due to vasodilation.
  • Short-acting CCBs were found to increase morbidity and mortality in chronic HF patients.

Purpose:

  • To evaluate the efficacy and safety of various calcium channel blockers in the context of heart failure treatment.
  • To explore the mechanisms behind the adverse effects of short-acting CCBs in HF.
  • To investigate the potential of newly developed CCBs for managing chronic heart failure.

Summary:

  • Short-acting CCBs can exacerbate HF by increasing sympathetic activity and heart rate.
  • Long-acting amlodipine demonstrated a neutral effect on HF morbidity and mortality.

Related Experiment Videos

  • Novel CCBs targeting different calcium channels or sympathetic activity, and those with protective effects (nitric oxide, antioxidant), are promising for HF treatment.

    • Impact:

    • Highlights the differential effects of CCB subclasses on heart failure outcomes.
    • Identifies risks associated with certain CCBs in HF patients.
    • Suggests new therapeutic avenues for managing chronic heart failure with advanced CCB formulations.